Long-Term Survival after Radiofrequency Ablation of Lung Oligometastases from Five Types of Primary Lesions: A Retrospective Evaluation

Omae, Kenichi; Hiraki, Takao; Gobara, Hideo; Iguchi, Toshihiro; Fujiwara, Hiroyasu; Matsui, Yusuke; Toyooka, Shinichi; Nagasaka, Takeshi; Kanazawa, Susumu

doi:10.1016/j.jvir.2016.05.017

Cited by 19 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were 34 studies[ 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 ] identified in this network meta-analysis [ Figure 1 ]. These included 17 studies from Europe/America and 17 studies from East Asia.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of thermal ablation of lung malignancies: A Network meta-analysis

et al. 2018

View full text Add to dashboard Cite

OBJECTIVE:The objective of this study was to compare the efficacy and safety of radiofrequency ablation (RFA), cryoablation, and microwave ablation (MWA) for patients with lung malignancies.METHODS:We performed a network meta-analysis to identify both direct and indirect evidence from relevant trials by searching PubMed, Embase, and the Cochrane Library to December 31, 2017, for the treatment of malignant lung tumors with the use of RFA, MWA, or cryoablation. We extracted the relevant information from the published studies with a predefined data sheet and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (local progression rate and overall survival rate) and safety (major complications rate). We did a random-effects network meta-analysis within a Bayesian framework as well as assessed the quality of evidence contributing to each network estimate using GRADE framework.RESULTS:We collected 34 studies eligible which included 1840 participants and 2520 lung malignancies (1318 primary lung cancer and 1202 pulmonary metastatic tumors). The quality of evidence was rated as very low in most comparisons. From the point of local progression rate, RFA and MWA were significantly more effective than cryoablation with odds ratio (OR) of 0.04 (95% confidence interval [CI]: 0.004, 0.38; P = 0.005) and 0.02 (95% CI: 0.002, 0.24; P = 0.001), respectively. No significant difference was found between MWA and RFA with an OR of 0.63 (95% CI: 0.04, 10.39; P = 0.745). Regarding the major complications, RFA, MWA, and cryoablation showed the comparable safety (P > 0.05).CONCLUSION:RFA and MWA offer an advantage over cryoablation for patients with malignant lung tumors.

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of thermal ablation of lung malignancies: A Network meta-analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Extrahepatic metastasis is one of the most important predictors of poor OS 9 , 10 . Several studies have investigated therapies for oligometastases, with promising results 11 - 13 . Niibe et al reported a 2-year OS rate of 65.7% in patients with pulmonary oligometastases 12 .…”

Section: Discussionmentioning

confidence: 99%

Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis

Chen

Zhang

et al. 2018

J. Cancer

View full text Add to dashboard Cite

Background: Sorafenib has been recommended as the standard therapy for advanced HCC with extrahepatic metastasis. The purpose of this retrospective study was to investigate the difference in overall survival (OS) between treatments with sorafenib combined with regional therapies versus sorafenib monotherapy in hepatocellular carcinoma (HCC) patients with pulmonary oligometastases.Methods: The study retrospectively enrolled 95 consecutive patients who underwent sorafenib therapy. A combined group (CG) of 40 patients received regional therapy in addition to sorafenib, and a monotherapy group (MG) of 55 patients received only sorafenib. OS was the primary endpoint, and time to progression (TTP) was the secondary endpoint. Subgroup analysis was further performed to evaluate the differences between the two groups. A propensity score-matched analysis was performed to overcome the bias.Results: Median OS was significantly longer in the CG than in the MG (18.37 vs. 7.13 months; P = 0.002). Multivariate analysis identified three baseline characteristics that were prognostic indicators of OS: macrovascular invasion, regional therapy, and alpha-fetoprotein. Median TTP was significantly longer in the CG than in the MG (2.93 vs. 2.23 months; P = 0.004). Further multivariate analysis showed alpha-fetoprotein, total bilirubin, and regional therapy as prognostic indicators of TTP. After propensity score matching, 34 paired patients constituted each group. Patients in the adjusted CG showed a longer OS and TTP than those in the adjusted MG (OS: 18.37 vs. 7.37 months, P = 0.015; TTP: 3.12 vs. 2.265 months, P = 0.009). Multivariate analysis showed that combining regional therapies was still a prognostic indicator of OS (P = 0.01) and TTP (P = 0.001).Conclusions: Sorafenib combined with regional therapies may be associated with prolonged OS and TTP in HCC patients with pulmonary oligometastases compared with sorafenib monotherapy.

show abstract

“…Most series evaluating RFA for metastatic disease report local progression rates of 10-30%, especially for lesions larger than 3 cm [14,18,63,[69][70][71]. Omae et al [72] reported longterm follow-up in 123 patients with lung oligometastases treated with RFA. The authors found a 5-year OS rate and recurrencefree survival rate of 62% and 25% [72].…”

Section: Metastatic Diseasementioning

confidence: 99%

“…Omae et al [72] reported longterm follow-up in 123 patients with lung oligometastases treated with RFA. The authors found a 5-year OS rate and recurrencefree survival rate of 62% and 25% [72].…”

Section: Metastatic Diseasementioning

confidence: 99%

The Role of Percutaneous Image-Guided Thermal Ablation for the Treatment of Pulmonary Malignancies

Mouli

Kurilova

Sofocleous

et al. 2017

American Journal of Roentgenology

View full text Add to dashboard Cite

show abstract

Long-Term Survival after Radiofrequency Ablation of Lung Oligometastases from Five Types of Primary Lesions: A Retrospective Evaluation

Abstract: Data from this single-center study appear promising in terms of long-term survival after RF ablation of lung oligometastases from 5 primary lesions.

Cited by 19 publications

References 22 publications

Efficacy and safety of thermal ablation of lung malignancies: A Network meta-analysis

Efficacy and safety of thermal ablation of lung malignancies: A Network meta-analysis

Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis

The Role of Percutaneous Image-Guided Thermal Ablation for the Treatment of Pulmonary Malignancies

Contact Info

Product

Resources

About